UBX — Unity Biotechnology Share Price
0.000.00%
Last trade - 00:00- $15.73m
- -$1.20m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -143.15% | ||
| Return on Equity | -231.27% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 4.78 | 0.24 | n/a | n/a | n/a | 14.87 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
UNITY Biotechnology, Inc. is a biotechnology company engaged in researching and developing therapeutics to slow, halt or reverse diseases of aging. The Company is focused on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. It is targeting specific biological mechanisms implicated in diseases of aging. Its core therapeutic approach targets cellular senescence, and it is advancing senolytic programs primarily in ophthalmologic disorders. It has other programs based on other biologies of aging to include an agonistic antibody to the Tie2 receptor and a Tie2/VEGF bispecific to treat vascular eye disease. UBX1325 is its advanced drug candidate for age-related diseases of the eye, including diabetic macular edema. UBX1325 is a potent small molecule inhibitor of BCL-xL. UBX2089, an a-Klotho hormone drug candidate, is being researched for multiple neurology indications.
Directors
- Keith Leonard CHM (59)
- Anirvan Ghosh CEO (57)
- Luis Visoso CFO (52)
- Nathan Guz VOP
- Jason Damiano VPR
- Alexander Nguyen GCN (41)
- Jamie Dananberg EXO (63)
- Nathaniel David DRC (53)
- Paul Berns IND
- Kristina Burow IND (47)
- Graham Cooper IND (51)
- Gilmore O Neill IND (56)
- Margo Roberts IND (66)
- Camille Samuels IND (50)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- March 30th, 2009
- Public Since
- May 3rd, 2018
- No. of Shareholders
- 40
- No. of Employees
- 16
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 17,212,172
- Address
- 285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, 94080
- Web
- https://unitybiotechnology.com/
- Phone
- +1 6504161192
- Auditors
- Ernst & Young LLP
Upcoming Events for UBX
Q2 2025 UNITY Biotechnology Inc Earnings Release
Q3 2025 UNITY Biotechnology Inc Earnings Release
Similar to UBX
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Unity Biotechnology share price?
As of Today at 17:53 UTC, shares in Unity Biotechnology are trading at $0.91. This share price information is delayed by 15 minutes.
How has the Unity Biotechnology share price performed this year?
Shares in Unity Biotechnology last closed at $0.91 and the price had moved by -42.87% over the past 365 days. In terms of relative price strength the Unity Biotechnology share price has underperformed the S&P500 Index by -47.28% over the past year.
What are the analyst and broker recommendations for Unity Biotechnology?
The overall consensus recommendation for Unity Biotechnology is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Unity Biotechnology dividend yield?
Unity Biotechnology does not currently pay a dividend.
Does Unity Biotechnology pay a dividend?
Unity Biotechnology does not currently pay a dividend.
When does Unity Biotechnology next pay dividends?
Unity Biotechnology does not currently pay a dividend.
How do I buy Unity Biotechnology shares?
To buy shares in Unity Biotechnology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Unity Biotechnology?
As of the previous close price of $0.91, shares in Unity Biotechnology had a market capitalisation of $15.73m.
Where are Unity Biotechnology shares listed?
Here are the trading details for Unity Biotechnology:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: UBX
What kind of share is Unity Biotechnology?
Based on an overall assessment of its quality, value and momentum Unity Biotechnology is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Unity Biotechnology share price forecast for 2025?
The analyst consensus target price for shares in Unity Biotechnology is $5.00. That is 446.99% above the last closing price of $0.91.
Analysts covering Unity Biotechnology currently have a consensus Earnings Per Share (EPS) forecast of -$1.29 for the next financial year.
Find out moreWhat is the trend in the Unity Biotechnology share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Unity Biotechnology. Over the past six months, its share price has underperformed the S&P500 Index by -17.16%.
As of the last closing price of $0.91, shares in Unity Biotechnology were trading -36.15% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Unity Biotechnology PE Ratio?
The Unity Biotechnology PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.91.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Unity Biotechnology?
Unity Biotechnology's management team is headed by:
- Keith Leonard - CHM
- Anirvan Ghosh - CEO
- Luis Visoso - CFO
- Nathan Guz - VOP
- Jason Damiano - VPR
- Alexander Nguyen - GCN
- Jamie Dananberg - EXO
- Nathaniel David - DRC
- Paul Berns - IND
- Kristina Burow - IND
- Graham Cooper - IND
- Gilmore O Neill - IND
- Margo Roberts - IND
- Camille Samuels - IND